Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Mayo Score kolīta čūlu slimības gadījumā× | Hārvija-Bredšova indekss× | |
|---|---|---|
| Nozare | Gastroenteroloģija | Gastroenteroloģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 1987 | 1980 |
| Autors≠ | Schroeder, K. W., Tremaine, W. J., and Ilstrup, D. M. | R. F. Harvey and J. M. Bradshaw |
| Tips | Clinician-rated | Clinician-rated |
| Pirmavots≠ | Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. New England Journal of Medicine, 317(26), 1625–1629. DOI ↗ | Harvey, R. F., & Bradshaw, J. M. (1980). A simple index of Crohn's-disease activity. Lancet, 315(8167), 514. DOI ↗ |
| Citi nosaukumi≠ | Mayo Clinic Score, UC Mayo Score | HBI |
| Saistītās≠ | 4 | 5 |
| Kopsavilkums≠ | The Mayo Score is a validated tool for assessing disease activity in ulcerative colitis, integrating clinical symptoms and endoscopic findings. Introduced by Schroeder and colleagues in 1987, it has become the reference standard for UC activity assessment in clinical trials and practice. The score combines stool frequency, rectal bleeding, overall physician global assessment, and endoscopic subscore into a single 0–12 scale. | The Harvey-Bradshaw Index (HBI) is a simple, clinician-administered tool for assessing disease activity in Crohn's disease. Developed in 1980, it measures five clinical parameters including abdominal pain, stool frequency, and extraintestinal manifestations. The HBI is widely used in clinical practice and research for monitoring disease progression and treatment response. |
| ScholarGateDatu kopa ↗ |
|
|